Tonix Pharmaceuticals Adds 9M Medicare Lives for TONMYA Coverage

Tonix Pharmaceuticals Holding Corp. has finalized a major managed Medicare agreement for its prescription fibromyalgia medication, TONMYA. The national contract adds approximately 9 million Medicare lives to the drug's coverage network, representing roughly 16 percent of the total United States Medicare population.

The managed care agreement officially takes effect on January 1, 2027. Union County Life tracked the expansion, which follows two previous commercial insurance coverage agreements completed by the clinical developer during the second quarter of 2026. With regional Medicaid availability already active across most states, the company's total projected pharmacy footprint will expand to 145 million covered lives, or 46 percent of the insured domestic market, by the start of the new year.

The U.S. Food and Drug Administration (FDA) approved TONMYA on August 15, 2025, as the first new prescription medicine for adult fibromyalgia management in more than 15 years. The chronic condition affects over 10 million adults across the United States. To support the commercial launch, the biopharmaceutical firm expanded its dedicated field sales force to 150 representatives by the third quarter of 2026. President and Chief Executive Officer Seth Lederman noted that patient access is accelerating significantly heading into the winter cycle.

FAQ:

When does the new Medicare coverage for TONMYA take effect?
The new managed Medicare agreement goes into effect on January 1, 2027, adding 9 million lives to the system.

What specific medical condition is TONMYA approved to treat?
The FDA approved the sublingual tablets on August 15, 2025, for the management of fibromyalgia in adult patients.

How long does Tonix Pharmaceuticals hold market exclusivity for this drug?
The company states that its current patents are projected to provide domestic market exclusivity until 2034.